Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Teleophthalmology: a strategy for timely diagnosis of sight-threatening diabetic retinopathy in primary care, Concepción, Chile.

Avendaño-Veloso A, Parada-Hernández F, González-Ramos R, Dougnac-Osses C, Carrasco-Sáez JL, Scanlon PH.

Int J Ophthalmol. 2019 Sep 18;12(9):1474-1478. doi: 10.18240/ijo.2019.09.16. eCollection 2019.

2.

Direct Ophthalmic Healthcare Resource Use among Patients with Geographic Atrophy in a Large Cohort from the United Kingdom.

Chakravarthy U, Bailey CC, Scanlon PH, McKibbin M, Khan RS, Mahmood S, Downey L, Dhingra N, Brand C, Brittain CJ, Willis JR, Venerus A, Muthutantri A, Cantrell RA.

Ophthalmol Retina. 2019 Nov;3(11):920-926. doi: 10.1016/j.oret.2019.06.012. Epub 2019 Jul 8.

PMID:
31416764
3.

QUALITY IMPROVEMENT OF LASER TREATMENT (QUILT)A New Retinal Laser Simulation System for Training in Resource-Poor Countries.

Muqit MMK, Aldington SJ, Scanlon PH.

Retina. 2019 Jul;39(7):1430-1434. doi: 10.1097/IAE.0000000000002586. No abstract available.

4.

Update on Screening for Sight-Threatening Diabetic Retinopathy.

Scanlon PH.

Ophthalmic Res. 2019;62(4):218-224. doi: 10.1159/000499539. Epub 2019 May 27. Review.

5.

The Case for Extended Screening Intervals for People With Diabetes and No or Minimal Retinopathy at Baseline.

van Wijngaarden P, Keel S, Scanlon PH.

JAMA Ophthalmol. 2019 Apr 1;137(4):449-450. doi: 10.1001/jamaophthalmol.2018.6901. No abstract available.

PMID:
30730543
6.

Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy.

Leal J, Luengo-Fernandez R, Stratton IM, Dale A, Ivanova K, Scanlon PH.

Eye (Lond). 2019 Apr;33(4):640-647. doi: 10.1038/s41433-018-0297-7. Epub 2018 Nov 30.

7.

Screening Intervals for Diabetic Retinopathy and Implications for Care.

Scanlon PH.

Curr Diab Rep. 2017 Sep 5;17(10):96. doi: 10.1007/s11892-017-0928-6. Review.

8.

Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease.

Gale R, Scanlon PH, Evans M, Ghanchi F, Yang Y, Silvestri G, Freeman M, Maisey A, Napier J.

Eye (Lond). 2017 May;31(S1):S1-S20. doi: 10.1038/eye.2017.53.

9.

Factors determining uptake of diabetic retinopathy screening in Oxfordshire.

Moreton RBR, Stratton IM, Chave SJ, Lipinski H, Scanlon PH.

Diabet Med. 2017 Jul;34(7):993-999. doi: 10.1111/dme.13350. Epub 2017 Apr 10.

10.

The English National Screening Programme for diabetic retinopathy 2003-2016.

Scanlon PH.

Acta Diabetol. 2017 Jun;54(6):515-525. doi: 10.1007/s00592-017-0974-1. Epub 2017 Feb 22. Review.

11.

Risk of diabetic retinopathy at first screen in children at 12 and 13 years of age.

Scanlon PH, Stratton IM, Bachmann MO, Jones C, Leese GP; Four Nations Diabetic Retinopathy Screening Study Group.

Diabet Med. 2016 Dec;33(12):1655-1658. doi: 10.1111/dme.13263. Epub 2016 Oct 19.

12.

The use of statistical methodology to determine the accuracy of grading within a diabetic retinopathy screening programme.

Oke JL, Stratton IM, Aldington SJ, Stevens RJ, Scanlon PH.

Diabet Med. 2016 Jul;33(7):896-903. doi: 10.1111/dme.13053. Epub 2016 Jan 10. Erratum in: Diabet Med. 2019 Oct;36(10):1319.

13.

Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening.

Scanlon PH, Aldington SJ, Leal J, Luengo-Fernandez R, Oke J, Sivaprasad S, Gazis A, Stratton IM.

Health Technol Assess. 2015 Sep;19(74):1-116. doi: 10.3310/hta19740.

14.

Screening attendance, age group and diabetic retinopathy level at first screen.

Scanlon PH, Stratton IM, Leese GP, Bachmann MO, Land M, Jones C, Ferguson B; Four Nations Diabetic Retinopathy Screening Study Group.

Diabet Med. 2016 Jul;33(7):904-11. doi: 10.1111/dme.12957. Epub 2015 Oct 6.

15.

Attitudes, access and anguish: a qualitative interview study of staff and patients' experiences of diabetic retinopathy screening.

Hipwell AE, Sturt J, Lindenmeyer A, Stratton I, Gadsby R, O'Hare P, Scanlon PH.

BMJ Open. 2014 Dec 15;4(12):e005498. doi: 10.1136/bmjopen-2014-005498.

16.

The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial.

Scanlon PH, Loftus J, Starita C, Stratton IM.

Diabet Med. 2015 Jan;32(1):97-101. doi: 10.1111/dme.12593. Epub 2014 Oct 13.

17.

Influence of primary care practices on patients' uptake of diabetic retinopathy screening: a qualitative case study.

Lindenmeyer A, Sturt JA, Hipwell A, Stratton IM, Al-Athamneh N, Gadsby R, O'Hare JP, Scanlon PH.

Br J Gen Pract. 2014 Aug;64(625):e484-92. doi: 10.3399/bjgp14X680965.

18.

Epidemiological issues in diabetic retinopathy.

Scanlon PH, Aldington SJ, Stratton IM.

Middle East Afr J Ophthalmol. 2013 Oct-Dec;20(4):293-300. doi: 10.4103/0974-9233.120007. Review.

19.

Agreement between photographic screening and hospital biomicroscopy grading of diabetic retinopathy and maculopathy.

Healy R, Sallam A, Jones V, Donachie PH, Scanlon PH, Stratton IM, Johnston RL.

Eur J Ophthalmol. 2014 Jul-Aug;24(4):550-8. doi: 10.5301/ejo.5000404. Epub 2013 Dec 9.

PMID:
24338579
20.

Delay in diabetic retinopathy screening increases the rate of detection of referable diabetic retinopathy.

Scanlon PH, Aldington SJ, Stratton IM.

Diabet Med. 2014 Apr;31(4):439-42. doi: 10.1111/dme.12313. Epub 2013 Oct 17.

21.

Updating diabetic retinopathy screening lists using automatic extraction from GP patient records.

Scanlon PH, Provins EK, Craske S, Chave SJ, Aldington SJ, Martin CN, Stratton IM.

J Med Screen. 2013;20(3):111-7. doi: 10.1177/0969141313505747. Epub 2013 Sep 24.

PMID:
24064544
22.

The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010.

Scanlon PH, Stratton IM, Histed M, Chave SJ, Aldington SJ.

Acta Ophthalmol. 2013 Aug;91(5):e335-9. doi: 10.1111/aos.12074. Epub 2013 Apr 1.

23.

Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?

Ross AH, Donachie PH, Sallam A, Stratton IM, Mohamed Q, Scanlon PH, Kirkpatrick JN, Johnston RL.

Eye (Lond). 2013 Jan;27(1):56-64. doi: 10.1038/eye.2012.225. Epub 2012 Nov 23.

24.

A simple risk stratification for time to development of sight-threatening diabetic retinopathy.

Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH.

Diabetes Care. 2013 Mar;36(3):580-5. doi: 10.2337/dc12-0625. Epub 2012 Nov 12.

25.

The preferences of people with diabetes for diabetic retinopathy screening.

Scanlon PH.

Diabet Med. 2012 Jul;29(7):836-7. doi: 10.1111/j.1464-5491.2012.03630.x. No abstract available.

PMID:
22435655
26.

A potential pathway for managing diabetic patients with arterial emboli detected by retinal screening.

Hadley G, Earnshaw JJ, Stratton I, Sykes J, Scanlon PH.

Eur J Vasc Endovasc Surg. 2011 Aug;42(2):153-7. doi: 10.1016/j.ejvs.2011.04.031. Epub 2011 May 25.

27.

Agreement and reasons for disagreement between photographic and hospital biomicroscopy grading of diabetic retinopathy.

Sallam A, Scanlon PH, Stratton IM, Jones V, Martin CN, Brelen M, Johnston RL.

Diabet Med. 2011 Jun;28(6):741-6. doi: 10.1111/j.1464-5491.2011.03273.x.

PMID:
21342245
28.

The prevalence of retinopathy in men with Type 2 diabetes and obstructive sleep apnoea.

West SD, Groves DC, Lipinski HJ, Nicoll DJ, Mason RH, Scanlon PH, Stradling JR.

Diabet Med. 2010 Apr;27(4):423-30. doi: 10.1111/j.1464-5491.2010.02962.x.

PMID:
20536514
29.

Why do patients still require surgery for the late complications of Proliferative Diabetic Retinopathy?

Scanlon PH.

Eye (Lond). 2010 Mar;24(3):435-40. doi: 10.1038/eye.2009.320. Epub 2010 Jan 8. Review.

PMID:
20057509
30.

Diabetic retinopathy and socioeconomic deprivation in Gloucestershire.

Scanlon PH, Carter SC, Foy C, Husband RF, Abbas J, Bachmann MO.

J Med Screen. 2008;15(3):118-21. doi: 10.1258/jms.2008.008013.

PMID:
18927093
31.

The English national screening programme for sight-threatening diabetic retinopathy.

Scanlon PH.

J Med Screen. 2008;15(1):1-4. doi: 10.1258/jms.2008.008015.

PMID:
18416946
32.

Visual acuity measurement and ocular co-morbidity in diabetic retinopathy screening.

Scanlon PH, Foy C, Chen FK.

Br J Ophthalmol. 2008 Jun;92(6):775-8. doi: 10.1136/bjo.2007.128561. Epub 2008 Mar 20.

PMID:
18356262
33.

Reply to 'Evaluation of the effect of JPEG and JPEG2000 image compression on the detection of diabetic retinopathy'.

Atan D, Foy C, Scanlon PH.

Eye (Lond). 2008 Mar;22(3):471; author reply 473. Epub 2007 Nov 9. No abstract available.

PMID:
17992197
34.

Evaluation of postinjury hepatocyte function by central amino acid clearance.

Maull KI, Long CL, Wagner DA, Hunt CA, Scanlon PH, Laws HL.

J Invest Surg. 2007 Jan-Feb;20(1):35-40.

PMID:
17365405
35.

Reported symptoms and quality-of-life impacts in patients having laser treatment for sight-threatening diabetic retinopathy.

Scanlon PH, Martin ML, Bailey C, Johnson E, Hykin P, Keightley S.

Diabet Med. 2006 Jan;23(1):60-6.

PMID:
16409567
36.

The influence of age, duration of diabetes, cataract, and pupil size on image quality in digital photographic retinal screening.

Scanlon PH, Foy C, Malhotra R, Aldington SJ.

Diabetes Care. 2005 Oct;28(10):2448-53.

PMID:
16186278
38.

A pilot quality assurance scheme for diabetic retinopathy risk reduction programmes.

Garvican L, Scanlon PH.

Diabet Med. 2004 Oct;21(10):1066-74.

PMID:
15384952
39.

Comparison of two reference standards in validating two field mydriatic digital photography as a method of screening for diabetic retinopathy.

Scanlon PH, Malhotra R, Greenwood RH, Aldington SJ, Foy C, Flatman M, Downes S.

Br J Ophthalmol. 2003 Oct;87(10):1258-63.

40.

The effectiveness of screening for diabetic retinopathy by digital imaging photography and technician ophthalmoscopy.

Scanlon PH, Malhotra R, Thomas G, Foy C, Kirkpatrick JN, Lewis-Barned N, Harney B, Aldington SJ.

Diabet Med. 2003 Jun;20(6):467-74.

PMID:
12786681
41.

Gastric emptying in trauma patients.

Carlin CB, Scanlon PH, Wagner DA, Borghesi L, Geiger JW, Long CL.

Dig Surg. 1999;16(3):192-6.

PMID:
10436366
42.

Hemorrhage associated with cesarean delivery: when is transfusion needed?

Naef RW 3rd, Washburne JF, Martin RW, Magann EF, Scanlon PH Jr, Morrison JC.

J Perinatol. 1995 Jan-Feb;15(1):32-5.

PMID:
7650550
43.

Endothelium-derived relaxing factor responses in Doca-salt hypertensive rats.

Kirchner KA, Scanlon PH Jr, Dzielak DJ, Hester RL.

Am J Physiol. 1993 Sep;265(3 Pt 2):R568-72.

PMID:
8214147

Supplemental Content

Loading ...
Support Center